GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » EPS (Diluted)

CuraScientific (CuraScientific) EPS (Diluted) : $0.03 (TTM As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is CuraScientific EPS (Diluted)?

CuraScientific's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.03.

CuraScientific's EPS (Basic) for the three months ended in Sep. 2023 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.23.

CuraScientific's EPS without NRI for the three months ended in Sep. 2023 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $0.18.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


CuraScientific EPS (Diluted) Historical Data

The historical data trend for CuraScientific's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific EPS (Diluted) Chart

CuraScientific Annual Data
Trend Dec20 Dec21 Dec22
EPS (Diluted)
-80.00 -20.00 -1.12

CuraScientific Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.03 -0.23 -0.03 0.29 -0.01

Competitive Comparison of CuraScientific's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, CuraScientific's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CuraScientific's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CuraScientific's PE Ratio distribution charts can be found below:

* The bar in red indicates where CuraScientific's PE Ratio falls into.



CuraScientific EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

CuraScientific's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.268-0)/4.726
=-1.11

CuraScientific's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.716-0)/756.677
=-0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CuraScientific  (OTCPK:CSTF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


CuraScientific EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of CuraScientific's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


CuraScientific (CuraScientific) Business Description

Traded in Other Exchanges
N/A
Address
51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236
CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.
Executives
Paul Quentin Goyette director 2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed director, officer: Chief Executive Officer 333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen director C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette director 13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez director, officer: Chief Executive Officer 15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson director, officer: Chief Operating Officer 19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

Introducing Leaf of Faith

By Marketwired Marketwired 03-26-2019